#Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Bristol-Myers Squibb and Microsoft Collaboration Bristol-Myers Squibb ( BMY ) - a global leader in oncology, announced an agreement with Microsoft, a market leader in AI-powered radiology and clinica...

P

Prohost Biotech

Jan 22, 2026

Today About: Alnylam Pharmaceuticals, Bristol-Myers Squibb and Intellia Therapeutics

Friday, August 18, 2025 Solid Earning, revenue growth, President Trump signing crypto bills, and Crispr Therapeutics stocks finally surge with the stocks following are happening today in spite of ext...

P

Prohost Biotech

Jul 18, 2025

Why and How the Stock Market Rallied Plus a Combination That Treated a Severe Colorectal Cancer

Today's Stock Market Rally Today, Wednesday, April 9, 2025 the news started with Trump announcing a '90-day pause' on tariffs for most countries. What happened next was a rallying Stock Market with th...

P

Prohost Biotech

Apr 9, 2025

The United States FDA Approved Bristol Myers Squibb’s COBENFY™ - A First-In-Class Muscarinic Agonist for Schizophrenia in Adults

Bristol-Myers Squibb COBENFY™ Approval Bristol Myers Squibb ( BMY ) announced that the U.S. FDA has approved COBENFY™ (xanomeline and trospium chloride) for schizophrenia in adults. Schizophrenia is...

P

Prohost Biotech

Sep 27, 2024

Bristol-Myers Squibb Combination Improving the Treatment of Metastatic Melanoma; AbbVie Improving the Treatment of Crohn's Disease

Offsetting the Biotech Firms' Good News There is no doubt that good news is filling the media about outperformances of both development-stage small biotech firms and revenues-generating firms. This go...

P

Prohost Biotech

Jul 29, 2022

Bristol-Myers Squibb: Deucravacitinib Demonstrates Promising Results in Treating Systemic Lupus Erithematosus

Bristol-Myers Squibb Product Deucravacitinib Bristol-Myers Squibb ( BMY ) product deucravacitinib has demonstrated positive results from the Phase 2 PAISLEY study in comparison to placebo in patients...

P

Prohost Biotech

Jun 2, 2022

What's Going on with the Clinical-Stage Biotech Firms. See Also: Promising News From Evotec SE

The Clinical Stage Biotech Firms We have reasons to believe that some clinical-stage biotechnology firms, which have yet to generate revenues, have solid scientific fundamentals, breakthrough techno...

P

Prohost Biotech

Apr 9, 2022

The Omicron Variant and the Bizarre Stock Market Chaos

The Bizarre Assessment of Biotech Firms in the Stock Market The Clinical-Stage Biotechnology Firms We are witnessing inexplicable evaluations of clinical-stage biotechnology companies. Bizarre is the...

P

Prohost Biotech

Nov 30, 2021

Cassava Sciences Good News and an Unwarranted Sell-Off. A New Drug Approval for Bristol-Myers Squibb and ImmunoGen Quarterly Results

Cassava Sciences Inc Following Cassava Sciences Inc successful and promising presentations, all the titles of the news and articles written by fair professionals have been as follows: “Cassava Science...

P

Prohost Biotech

Jul 30, 2021

Why Merck KGaA, Darmstadt, Germany Paid Sutro Biopharma. See Also: BMY Approval of Zeposia for UC

Sutro Biopharma Receives Milestone Payment from Merck KGaA, Darmstadt, Germany Sutro Biopharma ( STRO ) announced that it has received a milestone payment under its collaboration and license agreement...

P

Prohost Biotech

Jun 1, 2021

An Important Agreement Between Bristol-Myers Squibb and Agenus

Bristol-Myers Squibb and Agenus Agreement for AGEN1777 Bristol-Myers Squibb ( BMY ) and Agenus ( AGEN ) today announced that they have entered into a definitive agreement under which Bristol Myers Squ...

P

Prohost Biotech

May 18, 2021

Compugen: First Quarter Financial Results, Accomplishments and Future Plans

Compugen Updated Trial Data Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology ( ASCO ) 2021 Annual Meeting Milestone ri...

P

Prohost Biotech

May 13, 2021

Sutro Biopharma: First Quarter Financial Results, Business Highlights and More

Sutro Biopharma Inc Sutro Biopharma ( STRO ) is a clinical-stage drug discovery, development and manufacturing company. Its expertise is in the application of precise protein engineering and rational...

P

Prohost Biotech

May 10, 2021

Editas Medicine: Business Highlights and Financial Results Reported

Editas Medicine Reporting Editas Medicine ( EDIT ) reported business highlights and financial results for the first quarter of 2021. The reporting started with James C. Mullen, Chairman, President and...

P

Prohost Biotech

May 5, 2021

Bristol-Myers Squibb: CHMP of the EMA Recommended Additional Approval of Onureg® as Maintenance Therapy for AML

European Authorities Recommended Additional Approval of Bristol-Myers Squibb Product Onureg® for AML Bristol-Myers Squibb ( BMY ) : The Committee for Medicinal Products for Human Use ( CHMP ) of the E...

P

Prohost Biotech

Apr 23, 2021

Inovio DNA Vaccine Candidate INO-4800 has Promising Results. Read Also: Sutro Biopharma Good News

Inovio Pharmaceuticals Promising Results for INO-4800 for COVID-19 Inovio Pharmaceuticals ( INO ) announces promising results of a study focusing on the human immune responses induced by Inovio DNA va...

P

Prohost Biotech

Apr 15, 2021

1m

2

News & Comments

Exelixis Latest News. See Also: TransMedics Group May Improve on Heart Transplants

Exelixis Latest News The latest news announced by Exelixis (EXEL) is the FDA acceptance of its New Drug Application (NDA) that evaluates the safety, tolerability, pharmacokinetics and preliminary anti...

P

Prohost Biotech

Apr 7, 2021

Exelixis CABOMETYX: Now Approved in Europe for First-Line Treatment of Renal Cell Carcinoma

Exelixis Boxed in on Good News Exelixis ( EXEL ) is one of the firms boxed in by rule of thumb traders and short-sellers who put enormous pressure on biotech firms regardless of their good news. We si...

P

Prohost Biotech

Apr 1, 2021

Your Questions, Our Answers

Prohost Portfolio PLUS (formerly The Week in Review) Your Questions, Our Answers In the upcoming issues of Prohost Portfolio PLUS, as with all our Tables, we will include observations and target chang...

P

Prohost Biotech

Mar 28, 2021

Compugen: Good News During Bad Market Days

The market is sinking in a furious mood caused by the failure to figure out the pathway of criteria, which is currently controlling the stocks’ volatile performances. Today we are posting good news co...

P

Prohost Biotech

Feb 23, 2021

1m

0